Inhibitor Therapeutics (INTI)
(Delayed Data from OTC)
$0.06 USD
0.00 (0.00%)
Updated Aug 7, 2024 10:03 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Inhibitor Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 3 | 1 | 0 | 1 | 3 |
Income After Depreciation & Amortization | -3 | -1 | 0 | -1 | -3 |
Non-Operating Income | 0 | 13 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -3 | 12 | 0 | -1 | -3 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -3 | 12 | 0 | -1 | -3 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -3 | 12 | 0 | -1 | -3 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -3 | -1 | 0 | -1 | -3 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -3 | -1 | 0 | -1 | -3 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 171.95 | 367.78 | NA | 371.93 | NA |
Diluted EPS Before Non-Recurring Items | -0.02 | 0.00 | NA | 0.00 | NA |
Diluted Net EPS (GAAP) | -0.02 | 0.03 | NA | 0.00 | -0.01 |
Fiscal Year end for Inhibitor Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.78 | 1.27 | 0.76 | 0.74 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -0.78 | -1.27 | -0.76 | -0.74 |
Non-Operating Income | NA | 0.09 | 0.11 | 0.09 | 0.09 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -0.68 | -1.17 | -0.66 | -0.65 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.68 | -1.17 | -0.66 | -0.65 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -0.68 | -1.17 | -0.66 | -0.65 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 172.08 | 171.95 | 172.01 | 171.97 |
Diluted EPS Before Non-Recurring Items | -99,999.00 | 0.00 | -0.01 | 0.00 | 0.00 |
Diluted Net EPS (GAAP) | -99,999.00 | 0.00 | -0.01 | 0.00 | 0.00 |